Difficulty: Medium
Average Score: 84%
Practice
A 52-year-old female presents to the emergency room with swelling over her right calf for the past 3 days. Her right calf is warm, erythematous, and tender to palpation. A duplex is performed and shows a deep vein thrombosis (DVT). This is her first DVT. She is started on warfarin and told that she must continue it for the next 3 months. What effect does warfarin have on the coagulation panel?
Correct answer
C
Rationale
The correct answer is C) Increases prothrombin time.
Warfarin is a vitamin K antagonist that works by inhibiting the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) in the liver. Prothrombin time (PT) measures the extrinsic pathway of the coagulation cascade and is prolonged by warfarin due to the decreased levels of clotting factors. Therefore, the PT is increased when a patient is on warfarin therapy.
A) Decreases partial thromboplastin time (PTT) is incorrect because warfarin specifically affects the extrinsic pathway, not the intrinsic pathway measured by PTT.
B) Decreases prothrombin time is incorrect because warfarin actually prolongs the PT due to decreased levels of clotting factors.
D) Increases partial thromboplastin time is incorrect because warfarin does not directly impact the intrinsic pathway, which is measured by PTT.
Understanding the effects of warfarin on the coagulation panel is crucial for healthcare professionals managing patients on anticoagulant therapy. Monitoring PT levels helps ensure the therapeutic efficacy and safety of warfarin treatment, preventing both thrombotic and bleeding complications. This knowledge is essential for nurses, pharmacists, and physicians involved in the care of patients with conditions like DVT.
Warfarin is a vitamin K antagonist that works by inhibiting the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) in the liver. Prothrombin time (PT) measures the extrinsic pathway of the coagulation cascade and is prolonged by warfarin due to the decreased levels of clotting factors. Therefore, the PT is increased when a patient is on warfarin therapy.
A) Decreases partial thromboplastin time (PTT) is incorrect because warfarin specifically affects the extrinsic pathway, not the intrinsic pathway measured by PTT.
B) Decreases prothrombin time is incorrect because warfarin actually prolongs the PT due to decreased levels of clotting factors.
D) Increases partial thromboplastin time is incorrect because warfarin does not directly impact the intrinsic pathway, which is measured by PTT.
Understanding the effects of warfarin on the coagulation panel is crucial for healthcare professionals managing patients on anticoagulant therapy. Monitoring PT levels helps ensure the therapeutic efficacy and safety of warfarin treatment, preventing both thrombotic and bleeding complications. This knowledge is essential for nurses, pharmacists, and physicians involved in the care of patients with conditions like DVT.